A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 09 Jul 2024 Planned primary completion date changed from 15 Apr 2024 to 1 Jan 2029.
- 03 Dec 2023 Planned End Date changed from 9 Sep 2031 to 8 Sep 2033.
- 03 Mar 2023 Planned number of patients changed from 168 to 153.